参考文献:[1]Zeng H,Ran X,An L,et al.Disparities in stage at diagnosis for five common cancersin China:a multicentre,hospital-based,observational study[J].Lancet Public Health,2021,6(12):e877-e887.DOI:10.1016/S2468-2667(21)00157-2.[2]Dignam JJ,Dukic V,Anderson SJ,et al.Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer[J].Breast Cancer Res Treat,2009,116(3):595602.DOI:10.1007/s10549-008-0200-5.[3]中国抗癌协会国际医疗与交流分会、中国医师协会肿瘤医师分会乳腺癌学组,激素受体阳性人表皮生长因子受体2阴性早期乳腺癌术后辅助治疗多基因检测应用专家共识,中华肿瘤杂志.2022;44(1):54-59.[4]Sparano JA,Gray RJ,Makower DF,et al.Adjuvant chemotherapyguided by a 21-gene expression assay in breast cancer[J].N EnglJ Med,2018,379(2):111-121.DOI:10.1056/NEJMoa1804710.[5]Sparano JA,Gray RJ,Ravdin PM,et al.Clinical and genomic risk to guide the use of adjuvant therapy for breast cancer[J].N Engl JMed,2019,380(25):2395-2405.DOI:10.1056/NEJMoa1904819.[6]Albain KS,Barlow WE,Shak S,et al.Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausaloestrogen-receptor-positive breast cancer on chemotherapy:a retrospective analysis of a randomised trial[J].Lancet Oncol,2010,11(1):55-65.DOI:10.1016/womenwithnode-positive,S1470-2045(09)70314-6.[7]Kalinsky K,Barlow WE,Gralow JR,et al.21-Gene assay to inform chemotherapy benefit in node-positive breast cancer[J].NEngl J Med,2021.[2021-11-01].https://www.nejm.org/doi/full/10.1056/NEJMoa2108873.DOI:10.1056/NEJMoa2108873.(published online ahead of print).[8]Cardoso F,van't Veer LJ,Bogaerts J,et al.70-Gene signature asan aid to treatment decisions in early-stage breast cancer[J].NEngl J Med,2016,375(8):717-729.DOI:10.1056/NEJMoa1602253.[9]Piccart M,van't Veer LJ,Poncet C,et al.70-gene signature as an aid for treatment decisions in early breast cancer:updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age[J].Lancet Oncol,2021,22(4):476488.DOI:10.1016/S1470-2045(21)00007-3. 声明:材料由阿斯利康支持,仅供医疗卫生专业人士参考审批编号:CN-102469*此文仅用于向医学人士提供科学信息,不代表本平台观点